{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"35.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Benign Neoplasm of Thyroid Gland"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"97.08","value":"305.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Goitre"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.95","value":"23.2"},{"groupId":"OG001","spread":"146.57","value":"110.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Hyperthyroidism"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.30","value":"46.9"},{"groupId":"OG001","spread":"62.06","value":"58.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Hypothyroidism"},{"categories":[{"measurements":[{"groupId":"OG001","value":"22.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Papillary Thyroid Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Thyroid Disorder"},{"categories":[{"measurements":[{"groupId":"OG001","value":"20.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Thyroid Mass"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"description":"TEAEs are all AEs (serious and non-serious) occurred, for the first time, on or after the first day of study treatment. AEs started before the first dose of study treatment but increased in severity (CTC grade) over the baseline will also be considered TEAEs.\n\nParticipants were followed for AEs from the first day of study treatment until at least 28 days after the last on-study treatment administration, or until all serious or study medication-related toxicities had resolved or were determined to be \"chronic\" or \"stable,\" whichever was later.\n\nThe treatment was administered to the participants from cycle1/day 1 up to 9 cycles or until relapse, secondary malignancy, death or withdraw for other reasons such as toxicity or withdraw of consent.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"AT population: All participants who received at least 1 dose of study drug with treatment assignments designated according to actual study treatment received.\n\nThe numbers of participants analyzed were the participants with any adverse event of special interest (AESI) and that one participant could have reported more than one AESI","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1 & Day 28); subsequent cycles (Day 1); end of treatment/withdrawal and 28 days post treatment, or until all serious or study medication-related toxicities had resolved or were determined to be \"chronic\" or \"stable,\" whichever was later","title":"Summary of Duration of Treatment-Emergent Adverse Events of Special Interest by MedDRA Preferred Terms (All Causalities, All Cycles)","type":"SECONDARY","unitOfMeasure":"Weeks"}